Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript

Core Insights - Compass is a monoclonal antibody discovery and development company focused on oncology, based in Boston [1] - The company currently has three drugs in clinical trials and a fourth drug set to enter the clinic [1] - 2026 is anticipated to be a significant year for the company with important updates expected [1] Drug Development Updates - The lead program, Tovecimig, is a DLL4xVEGF-A bispecific antibody, with readouts on secondary endpoints of progression-free survival and overall survival expected by the end of Q1 2026 [1] - In the second half of 2025, the company observed significant efficacy in a Phase I clinical trial of a PD-1, PD-L1 bispecific antibody, with three responses noted in the first 15 patients treated [2] - The company plans to expand cohorts for patients with triple-negative breast cancer and non-small cell lung cancer based on the observed efficacy [2]